iwNHL 2018 | Nuances of systemic lymphoma and CNS lymphoma
Speaking from the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France, Bianca Santomasso, MD, PhD, of Memorial Sloan Kettering Cancer Center, NY, discusses how some of the nuances that pertain to systemic lymphoma also have implications for CNS lymphoma, such as the use of interferon-α to treat certain lymphoproliferative situations. Dr Santomasso comments on the interesting observations in patients with systemic lymphoma, in which there are patients who develop neurologic toxicity from therapies and those who have CNS metastasis.
Transcript (edited for clarity)
For me – I’m a neuro-oncologist – I think that it’s been interesting. I have obviously an interest in CNS lymphoma and it’s been interesting to hear how some of the new molecular classifications and some of the nuances that pertain to systemic lymphoma also have implications for CNS lymphoma.
For example, using interferon-alpha to treat certain types of lymphoproliferative situations and that’s been interesting...
For me – I’m a neuro-oncologist – I think that it’s been interesting. I have obviously an interest in CNS lymphoma and it’s been interesting to hear how some of the new molecular classifications and some of the nuances that pertain to systemic lymphoma also have implications for CNS lymphoma.
For example, using interferon-alpha to treat certain types of lymphoproliferative situations and that’s been interesting. And also, we do see patients with systemic lymphoma, both that developed neurologic toxicity from therapies and also who have a CNS metastasis, so, it’s been a great refresher and a great conference; I’ve learned a lot.
Read more...
